Antiplatelet Aggregating Agents
Arterial or venous occlusion by blood clot are common occurrences in old age and the incidence rises as age progresses. They both give rise to considerable morbidity as well as mortality. The prevention of thrombosis and its consequences would inevitably promote and maintain health in old people. To attempt to do this is a worthy cause and it is not surprising that many people have set out along this road with much enthusiasm, but often little planning.
KeywordsPlatelet Aggregation Inhibit Platelet Function Thromboxane Synthetase Thrombin Induce Platelet Aggregation Anturan Reinfarction Trial
Unable to display preview. Download preview PDF.
- 2.E. de Brito Paiva, J. Borgykowski, and J. P. Junod, Physiotherapeutic prophylaxis of pulmonary embolism in the elderly high risk patient: Indications and limitations, J.Clin. Exp.Geront. 3: 245 (1981).Google Scholar
- 3.F. I. Pareti, P. M. Mannucci, Drugs affecting platelet behaviour, J.Roy.Coll.Phycns. 10: 194 (1976).Google Scholar
- 7.M. L. Steer, and E. W.I.Salzman, Cyclic nucleotides in hemostasis and thrombosis, in: “Advances in Cyclic Nucleotide Research, P. Hamer and H. Sands, eds., Vol. 12, Raven Press, New York (1980).Google Scholar
- 13.H. A. Smythe, M. A. Ogryzlo, E. A. Murphy, and J. F. Mustard, The effect of sulphinpyrazone (Anturan) on platelet economy and blood coagulation in man, Can.Med.Assoc.J. 92: 818 (1965).Google Scholar
- 17.Anturan Reinfarction Italian Study, Sulphinpyrazone in post-myocardial infarction, Lancet 1: 237 (1982).Google Scholar
- 18.The Persantir-Aspirin Reinfarction Study Research Group. Persantin and aspirin in coronary heart disease, Circulation 62: 449 (1980)Google Scholar
- 19.J. A. Blakely, and M. Gent, Platelets drugs and longevity in a geriatric population, in: “Platelets Drugs and Thrombosis,” J. Hirsh, J. F. Cade, A. S. Galius, eds., S. Karger, Basel (1975).Google Scholar